Print

DTRA Awards US$3.3M Contract to PsiOxus Therapeutics Limited to Develop Biodefence Vaccine Adjuvants  
1/18/2013 9:40:16 AM

OXFORD, England--(BUSINESS WIRE)--PsiOxus Therapeutics, Ltd. (PsiOxus), a development stage biotechnology company, today announced the award of a US$3.3 million contract from the US Defense Threat Reduction Agency (DTRA) to develop biodefence vaccine adjuvants using the company’s proprietary PolyMAP technology to help improve the safety and efficacy of two vaccines candidates: the recombinant Protective Antigen (rPA) for Anthrax and the Venezuelan Equine Encephalopathy Virus (VEEV). PolyMAP is an immunotherapeutic platform that combines polymers with synthetic adjuvants to significantly enhance the effectiveness of vaccines.
//-->